Kineta Board Member Boosts Stake Following Multiple Stock Transactions

Rhea-AI Filing Summary

Director David Arkowitz of Kineta reported multiple transactions on June 23-25, 2025:

• Exercised 12,500 stock options at $0.611 per share through conversion (M)
• Disposed of 4,706 shares at $0.26 per share through tax withholding (F)
• Received 6,000 new shares as an award (A) at $0

These transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. The merger agreement triggered full vesting of options granted under the 2022 Equity Incentive Plan. Following all transactions, Arkowitz directly owns 18,141 shares of common stock.

The transactions reflect significant insider activity coinciding with the company's merger approval, with the director both exercising options and receiving new equity compensation.

Insider Trade Summary

12,500 shares exercised/converted

Mixed 4 txns

Insider Arkowitz David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,000	$0.00	--
Exercise	Stock Option (Right to Buy)	12,500	$0.00	--
Exercise	Common Stock	12,500	$0.611	$8K
Tax Withholding	Common Stock	4,706	$0.26	$1K

Holdings After Transaction: Common Stock — 18,141 shares (Direct); Stock Option (Right to Buy) — 0 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arkowitz David

(Last) (First) (Middle)

C/O KINETA, INC.

7683 SE 27TH STREET, SUITE 481

(Street)

MERCER ISLAND WA 98040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2025		M		12,500	A	$0.611	16,847	D
Common Stock	06/23/2025		F		4,706	D	$0.26	12,141	D
Common Stock	06/25/2025		A		6,000	A	$0	18,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.611	06/23/2025		M			12,500	(1)	09/03/2034	Common Stock	12,500	$0	0	D

Explanation of Responses:

1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.

	/s/ Nanette Agustines, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did David Arkowitz make in KA stock on June 23, 2025?

On June 23, 2025, David Arkowitz exercised 12,500 stock options at $0.611 per share (Code M) and had 4,706 shares withheld for taxes (Code F) at $0.26 per share. Additionally, he received 6,000 shares on June 25, 2025 as a stock award.

How many shares of Kineta (KA) does David Arkowitz own after these transactions?

After the reported transactions, David Arkowitz directly owns 18,141 shares of Kineta (KA) common stock.

What was the exercise price of KA stock options that David Arkowitz exercised?

David Arkowitz exercised stock options with an exercise price of $0.611 per share. These options were originally set to expire on September 3, 2034, but were exercised early due to a merger agreement with TuHURA Biosciences.

Why did David Arkowitz's KA stock options vest early on June 23, 2025?

The stock options vested early due to an Optionholder Treatment Agreement dated June 16, 2025, and a merger agreement between Kineta and TuHURA Biosciences. This accelerated vesting was approved by stockholders at a Special Meeting held on June 23, 2025.